• Publications
  • Influence
Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal haematological diseases characterized by ineffective haematopoiesis and predisposition to acute myeloid leukaemia (AML). TheExpand
  • 514
  • 30
Integrated profiling of basal and luminal breast cancers.
Basal and luminal are two molecular subtypes of breast cancer with opposite histoclinical features. We report a combined, high-resolution analysis of genome copy number and gene expression in primaryExpand
  • 256
  • 21
  • PDF
Prognostic and predictive value of PDL1 expression in breast cancer
Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different carcinomas withExpand
  • 260
  • 18
  • PDF
Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer
In human carcinomas, especially breast cancer, chromosome arm 8p is frequently involved in complex chromosomal rearrangements that combine amplification at 8p11-12, break in the 8p12-21 region, andExpand
  • 205
  • 12
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
Chronic myelomonocytic leukaemia (CMML) is a haematological disease currently classified in the category of myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) because of its dualExpand
  • 167
  • 10
  • PDF
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
BackgroundOncogene amplification and overexpression occur in tumor cells. Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. ChromosomalExpand
  • 123
  • 10
  • PDF
Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer
Introduction ECRG4/C2ORF40 is a potential tumor suppressor gene (TSG) recently identified in esophageal carcinoma. Its expression, gene copy number and prognostic value have never been explored inExpand
  • 95
  • 9
  • PDF
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
BackgroundThe lastly identified claudin-low (CL) subtype of breast cancer (BC) remains poorly described as compared to the other molecular subtypes. We provide a comprehensive characterization of theExpand
  • 90
  • 8
  • PDF
ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.
Cancer stem-like cells (CSC) have been widely studied, but their clinical relevance has yet to be established in breast cancer. Here, we report the establishment of primary breast tumor-derivedExpand
  • 99
  • 5
  • PDF
Genome profiling of ERBB2-amplified breast cancers
BackgroundAround 20% of breast cancers (BC) show ERBB2 gene amplification and overexpression of the ERBB2 tyrosine kinase receptor. They are associated with a poor prognosis but can benefit fromExpand
  • 142
  • 5